安脱达标准化尘螨疫苗治疗变应性鼻炎的疗效和安全性评价

The efficacy and safety of subcutaneous immuno-therapy with dermatophagoides pteronyssinus for allergic rhinitis

目的:评价安脱达标准化尘螨疫苗免疫治疗变应性鼻炎的疗效及安全性。方法:对68例尘螨变应性鼻炎(AR)患者进行特异性免疫治疗前及治疗2年后的症状和体征评分,比较其治疗效果,同时计算不良反应发生率。通过症状评分、鼻炎相关生活质量评分和不良反应分级评价免疫治疗的疗效和安全性。结果:经过2年治疗后,特异性免疫治疗患者症状评分和药物评分较治疗前均明显减少(P<0.01)。同时,免疫治疗组患者的鼻炎相关生活质量明显改善。所有免疫治疗患者未出现严重不良反应。结论:标准化特异性免疫治疗可以安全有效地治疗变应性鼻炎。

Objective：To evaluate the efficacy and safety of subcutaneous immunotherapy with a standardized Dermatophagoides pteronyssinus extract for allergic rhinitis.Method：Sixty-eight patients with allergic rhinitis who received specific immunotherapy with a standardized dermatophagoides pteronyssinus extract were enrolled in this study.The clinical symptoms and signs were scored before and 2 years after treatment.Side effects were registered.Symptom and side effect scores were assessed to evaluate the clinical efficacy and safety.Result：There was a significant difference（P0.01） in symptom and medication scores between the two groups tow years after treatment.The patients had fewer symptoms and lower intake of medication.No severe systemic reactions were registered.Conclusion：Immunotherapy with a standardized dermatophagoides pteronyssinus extract is effective and safe to treat patients clinically sensitive to this allergen.